Liso-Cel Shows Promise in High-Risk Diffuse Large B-Cell Lymphoma
June 7th 2018A promising CD19-directed chimeric antigen (CAR) T-cell therapy, Lisocabtagene maraleucel (JCAR017; liso-cel), may result in durable remissions among patients with high-risk diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.
Mobile Monitoring Technology Helps to Reduce Symptom Severity in HNC
June 4th 2018Patients with head and neck cancer (HNC) who tracked their symptoms using the CYCORE (CYberinfrastructure for COmparative Effectiveness REsearch) system’s mobile and sensor technology experienced reduced symptom severity compared with those who received standard care, according to results of a large randomized trial.
Relieving Nausea With Olanzapine in Patients Treated for Head and Neck Cancer
June 18th 2015Nausea and vomiting associated with anticancer therapies continue to be among patients' most troubling symptoms. Findings of a clinical trial found that olanzapine demonstrated comparative benefits in relieving these symptoms.